Article: article from journal or magazin.
Ruthenium porphyrin compounds for photodynamic therapy of cancer.
Journal of Medicinal Chemistry
Five 5,10,15,20-tetra(4-pyridyl)porphyrin (TPP) areneruthenium(II) derivatives and a p-cymeneosmium and two pentamethylcyclopentadienyliridium and -rhodium analogues were prepared and characterized as potential photosensitizing chemotherapeutic agents. The biological effects of all these derivatives were assessed on human melanoma tumor cells, and their cellular uptake and intracellular localization were determined. All molecules, except the rhodium complex which was not cytotoxic, demonstrated comparable cytotoxicity in the absence of laser irradiation. The ruthenium complexes exhibited excellent phototoxicities toward melanoma cells when exposed to laser light at 652 nm. Cellular uptake and localization microscopy studies of [Ru 4(eta (6)-C 6H 5CH 3) 4(TPP)Cl 8] and [Rh 4(eta (5)-C 5Me 5) 4(TPP)Cl 8] revealed that they accumulated in the melanoma cell cytoplasm in granular structures different from lysosomes. The fluorescent porphyrin moiety and the metal component were localized in similar structures within the cells. Thus, the porphyrin areneruthenium(II) derivatives represent a promising new class of organometallic photosensitizers able to combine chemotherapeutic activity with photodynamic therapeutic treatment of cancer.
Antineoplastic Agents, Cell Line, Tumor, Cell Proliferation, Cytoplasmic Granules, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Humans, Lasers, Lysosomes, Melanoma, Models, Molecular, Molecular Structure, Organometallic Compounds, Photochemotherapy, Photosensitizing Agents, Porphyrins, Ruthenium, Tissue Distribution
Web of science
Last modification date